Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE SC: Efgartigimod PH20 SC in Adult Primary Immune Thrombocytopenia
jRCT2071210025Phase 3Completed
- Sponsor
- argenx
- Start
- Aug 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in immune thrombocytopenia (ITP) comparing Efgartigimod PH20 SC with Placebo PH20 SC (2 arms). Primary endpoint: Sustained platelet count response in chronic ITP. Started Aug 2021; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on jRCT2071210025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210025.